These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 36528491)

  • 1. Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.
    Liu F; Wang Z; Li X; Zhang Z; Yang Y; Chen J; Chen D; Wu L; Liu X; Han S; Wang F; Wahafu W; Gao Y; Ren S; Xing N; Cai G; Chen X
    Cancer Commun (Lond); 2023 Feb; 43(2):214-224. PubMed ID: 36528491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis.
    Mei T; Wang T; Deng Q; Gong Y
    Front Immunol; 2023; 14():1062679. PubMed ID: 36825025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: Systematic review and meta-analysis of real-world evidence.
    Xie W; Xiao S; Li X; Huang J; Li G; Zhang Z
    Eur J Intern Med; 2023 Sep; 115():88-95. PubMed ID: 37263805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis.
    Liu K; Qin Z; Xu X; Li T; Ge Y; Mao H; Xing C
    Front Oncol; 2021; 11():662731. PubMed ID: 34221977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
    Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
    BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis.
    Wang S; Yan L; Yu J; Lu C
    Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3385-3395. PubMed ID: 38358507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
    Mao YT; Wang Y; Chen XX; Liu CJ; Bao Q
    J Cosmet Dermatol; 2024 Apr; 23(4):1165-1177. PubMed ID: 38013634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
    Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with immune check point inhibitors and acute kidney injury.
    Valentin A; Møller AKH; Palshof JA; Broberg B; Gravesen E; Svane IM; Hansen D
    Acta Oncol; 2023 Feb; 62(2):121-125. PubMed ID: 36755491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.
    Liu T; Jin B; Chen J; Wang H; Lin S; Dang J; Li G
    Ther Adv Med Oncol; 2020; 12():1758835920940927. PubMed ID: 32774474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials.
    Lima IG; Silva IBUCD; Pípolo VC; Delfino VDA; Bignardi PR
    Immunopharmacol Immunotoxicol; 2024 Aug; 46(4):470-481. PubMed ID: 38825890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
    Wang S; Lv H; Yu J; Chen M
    Int Immunopharmacol; 2024 Apr; 131():111884. PubMed ID: 38518592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study.
    Zhou P; Liu B; Shen N; Fan X; Lu S; Kong Z; Gao Y; Lv Z; Wang R
    Ren Fail; 2024 Dec; 46(1):2326186. PubMed ID: 38466161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of Proton Pump Inhibitor Use and Immune Checkpoint Inhibitor-Mediated Acute Kidney Injury: A Meta-Analysis and a Review of Related Outcomes.
    Mohan A; Krisanapan P; Tangpanithandee S; Thongprayoon C; Kanduri SR; Cheungpasitporn W; Herrmann SM
    Am J Nephrol; 2024; 55(4):439-449. PubMed ID: 38471492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
    Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
    Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
    [No Abstract]   [Full Text] [Related]  

  • 19. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
    Vardarli I; Tan S; Brandenburg T; Weidemann F; Görges R; Herrmann K; Führer D
    J Clin Endocrinol Metab; 2024 Mar; 109(4):1132-1144. PubMed ID: 37967245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.